Trial Profile
A Phase II Study of the Dual Immune Checkpoint Blockade With Durvalumab (MEDI4736) Plus Tremelimumab Following Palliative Hypofractionated Radiation in Patients With Microsatellite Stable (MSS) Metastatic Colorectal Cancer Progressing on Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2022
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 24 Jan 2020 Status changed from active, no longer recruiting to completed.
- 31 Jul 2019 Status changed from recruiting to active, no longer recruiting.
- 31 Jul 2019 Planned End Date changed from 1 Mar 2019 to 1 Jul 2019.